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Helenine was first obtained by Shope (1) in 1948 from Penicillium funiculo- 
sum. It has been reported to protect mice against swine  influenza,  Columbia 
SK encephalomyelitis, and  Semliki  Forest viruses (2, 3), and  to prevent the 
development of poliomyelitis in monkeys (4);  the protection was apparently 
achieved without adverse side effects.  It has been briefly reported by Gitter- 
man to inhibit the cytopathogenic effect of Semliki Forest virus grown in chick 
embryo fibroblast cell culture (5). 
Obviously, isolation  of helenine  is  of great  interest  in  both  practical  and 
theoretical virology; however, a serious effort of Lewis et al. has resulted only in 
partial purification (6).  One major difficulty was the wide fluctuation in anti- 
viral  activity of various crude helenine  preparations  freshly harvested from 
peniclllium  cultures  grown  under  presumably  identical  conditions.  In  our 
present attempt to isolate helenine  we were working on the hypothesis that an 
inhibitor to the antiviral agent is present in penicillium  culture. The hypothesis 
was suggested by our recent findings with Semliki  Forest virus: titers of viral 
hemagglutinin  in  fresh  homogenates  obtained  by identical  procedures  from 
baby mouse brain infected with the virus varied from 0 to 16 (7) and a small 
molecule inhibitor to the hemagglutinin was present in the infected brain prepa- 
rations (8). 
The present report describes a  test of the hypothesis that  an inhibitor  to 
helenine  may be present in the peniclllium  cultures. If a helenine  preparation 
should  contain  an  inhibitor,  dilution  of the  preparation  would decrease the 
concentration  of the inhibitor  as well as of the  active principle.  Hence,  one 
would expect antiviral activity to vary with dilution according  to the following 
pattern: Within the effective concentration range of the inhibitor, the decreases 
in antiviral activity should be smaller  than one would expect from the dilution 
ratios. When further dilution has reduced inhibitor concentrations below effective 
levels,  antiviral  activity will be decreased more rapidly,  in proportion  to the 
dilution ratio. Hence, variation of activity with dilution provides a test for the 
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inhibitor hypothesis. Our results confirm this hypothesis and offer a  new lead 
to the isolation of helenine. 
RESULTS 
A  freshly  prepared crude helenine preparation was titrated  at serial  2-fold 
dilutions for its activity  to inhibit  plaque formation in mouse L cell  layer by 
Semliki Forest virus according to a procedure  to be described later (9). In 
essence, this consists in pretreatment of the L cell layer for 21 hr with helenine 
before inoculation with virus. 
The results are given by the curve labeled "Whole Suspension" in  Fig.  1. 
Dilution of the preparation up to 8-fold resulted in a  steady decrease, rather 
than an increase in the plaque number; i.e., antiviral activity increased with 
the dilution. After a short leveling off between the 8- and 16-fold dilution points, 
the curve assumed a linear upward trend with a marked increase in steepness 
after the 128-fold dilution point. The results are consistent with the inhibitor 
hypothesis described above. 
To ascertain if the inhibitor can be separated from helenine by centrifugation, 
100 ml of the same helenine preparation was centrifuged (10 ml per tube) with a 
Spinco Model L ultracentrifuge in a No. 40 rotor for 2 hr at 40,000 l~P~ at 4- 
8°C. The resulting slightly reddish pellets were resuspended in 1% of the origi- 
nal volume in a solution of 0.15 M NaC1, 0.01 ~  sodium phosphates, and 0.0001 
MgC12, pH 7.0, followed by gentle stirring for 0.5 hr at 2-4°C. The resulting 
suspension was then assayed for plaque-inhibiting activity, together with the 
supernatant, on portions of the same batch of fresh L  cell monolayers as was 
used for the assay of the whole suspension. The whole suspension, as well as 
the supernatant, was stirred before assay under the same conditions as those 
employed for the pellet suspension. It has been found that the stirring did not 
produce a change in the antiviral activity of the whole suspension. 
The results are also shown in Fig. 1. The curve for the supernatant shows no 
reduction  in  plaque  number  through  the  entire  concentration  range  corre- 
sponding to the inhibition-to-helenine and inhibition-free zones for  the whole 
suspension. On the other hand, the pellet curve shows the reduction at all the 
dilutions studied. When the pellets were diluted to volumes 0.2 to 0.8 of the 
original volume of whole suspension, less  than  one plaque per  Petri dish,  or 
0.08 % of the number observed for whole suspension was seen. Further dilution 
resulted in a steady increase in plaque number. The slope of the dilution curve 
between 3.2- and 25.6-fold dilution points is similar to that of the whole suspen- 
sion at the inhibition-free zone. Therefore, inhibition to helenine was not ob- 
served with  the pellet. In other words, helenine free of inhibition can be ob- 
tained by the ultracentrifugation. 
These results are  consistent with  the  interpretation that  the inhibitor is a 
molecule much smaller than helenine. However, they do not exclude the possi- PING-YA0 CWF.NG AND RICHARD E. SHOPE  507 
bility that the inhibitor  was sedimented  and  inactivated  by the ultracentrifu- 
gation. 
A  20% reduction  in plaque number occurred at the 25.8-fold dilution  of the 
pellet.  Since  the  same reduction  was observed  at  about  the  516-fold  dilution 
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FIG. 1.  Dependence of number of Semliki Forest virus (SFV) plaques upon dilution. Three 
helenine  samples  were used  to pretreat L  cell layers; whole suspension,  supernatant,  and 
pellet. Values of 132 and ll9 plaques were obtained with duplicate assays in cell layers treated 
with the diluent.  The 1-fold dilution  point for the pellet preparation is that in which it was 
suspended in a volume equivalent to that of the whole suspension from which it was derived. 
of the  uncentrifuged  sample  in  the  inhibition-free  zone,  it  is  thus  concluded 
that  after  the  centrifugation  only about  5 %  of the  activity was recovered in 
the pellet.  It appears probable at first glance that the rest of the activity still 
remains with the supernatant  but is masked by the inhibitor.  However, this is 
shown  to  be unlikely  by  the  finding  that  no  helenine  activity  was  observed 508  INHIBITOR  FOR  HELENINE 
with  the  supernatant  even  at  dilutions  corresponding  to  the  inhibition-free 
zone of the uncentrifuged sample. The loss of activity was very likely a result 
of the  pelleting  of helenine.  Hence,  although  the  discovery of  the  inhibitor 
exposes the weakness of the previous experimental basis for the claim of Lewis 
et al. that all helenine is sedimented by ultracentrifugation (6), the results of 
our centrifugafion study nevertheless substantiate this claim. 
SUMMARy 
The present findings indicate that the wide fluctuation observed in the anti- 
viral activity of various crude helenine preparations may be attributable to the 
presence of varying amounts of inhibitor. Antiviral activity could be enhanced 
by removal of the inhibitor. A meaningful value for helenine fiter in a  prepa- 
ration clearly should be determined in the inhibitor-free zone. 
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